Isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
申请人:Neurogen Corporation
公开号:US06353103B1
公开(公告)日:2002-03-05
Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula
or the pharmaceutically acceptable salts thereof wherein Ar, R1, R2, R3, R4 and W are various organic and inorganic substituents.
本文披露了一种在人类CRF1受体上高度选择性的部分激动剂或拮抗剂,可用于诊断和治疗与压力相关的疾病,如创伤后应激障碍(PTSD),以及抑郁症、头痛和焦虑症。这些化合物具有以下结构式:
或其药用可接受的盐,其中Ar、R1、R2、R3、R4和W为各种有机和无机取代基。